Search | Clinical Trials Finder

Conditions: Graft Vs Host Disease, Graft-versus-host-disease
Interventions: CliniMacs®; Device
Lead sponsor: Christopher Dvorak; Other
Eligibility: Up to 30 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Granulomatous Disease
Interventions: Stem cell transplantation; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thrombotic Thrombocytopenic Purpura
Interventions: Danazol; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis, Leukapheresis, Fludarabine Phosphate; Biological · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2039
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sarcoma
Interventions: F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Malignancies
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Solid Tumor, Healthy, Malignant Solid Neoplasm
Interventions: Blood Draw, Apheresis; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Sickle Cell Disease
Interventions: Motixafortide; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Bethesda, Maryland • Memphis, Tennessee

Conditions: Non-Hodgkin's Lymphoma
Interventions: Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Duarte, California • Aurora, Colorado

Conditions: Autologous Stem Cell Transplantation
Interventions: G-CSF plus plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Neuroblastoma, Lymphoma, High-risk Tumor
Interventions: CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS; Biological · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
Interventions: Plasma exchange, Daratumumab; Procedure · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreas Cancer, Pancreatic Cancer
Interventions: EGFR FPBMC; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Sarcoma
Interventions: Doxorubicin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: DOCK8 Deficiency
Interventions: Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan), Total Body Irradiation (TBI), Busulfan (Busulfex), Donor peripheral blood stem cell mobiliation and collection, Bone Marrow Harvest Procedure; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Lupus Erythematosus
Interventions: Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more

Conditions: Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions: Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Focal Segmental Glomerulosclerosis
Interventions: No intervention; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Dialysis Amyloidosis
Interventions: Lixelle® treatment; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Marrow Failure Syndrome
Interventions: Filgrastim, Plerixafor, Leukapheresis; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Islet Transplantation
Interventions: Infusion of recipient T regulatory cell, Infusion of concomitant Donor Derived Vertebral Bone Marrow; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia
Interventions: sargramostim, busulfan, cyclophosphamide, dexamethasone, etoposide, bone marrow transplantation, hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis; Biological · Procedure · Drug + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

Pilot Study: Effects of G-CSF on T Cell Function

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors

Ex Vivo Expansion (ACT-X)

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

LDL-Apheresis for FSGS CardioRenal Outcomes

Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer